Orbit summarizes health news from several newsrooms. It is not medical advice. Talk to a doctor or pharmacist about your own health.
At a glance
Moderna and Merck released full trial data for their investigational melanoma cancer vaccine.123
The experimental treatment reduced the risk of melanoma recurrence or death by 42%.23
Financial reporting noted that company shares fell following the data release.12
Where sources agree
- Moderna and Merck released melanoma vaccine data3 of 3
- Trial results showed a 42% risk reduction2 of 3
Who covered this
3 National
Sources
- 1CNBCModerna shares plunge after cancer vaccine data leaks — despite positive results ↗
- 2MarketWatchModerna’s cancer vaccine hits its targets, but a data leak rattled investors and the stock tumbled ↗
- 3STATSTAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial ↗
Based on reporting from these reputable newsrooms and reviewed by Orbit’s editors. A fact appears only when at least two sources report it. Orbit is not affiliated with these publishers.
